{"title":"Anfotericina B liposomal en el tratamiento de la leishmaniasis visceral","authors":"Begoña Monge-Maillo, Rogelio López-Vélez","doi":"10.1016/j.riam.2021.04.002","DOIUrl":null,"url":null,"abstract":"<div><p>A review on the current evidence of the efficacy and security of liposomal amphotericin<!--> <!-->B (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10<!--> <!-->mg/kg has shown effectiveness in the treatment of VL due to <em>Leishmania donovani</em>. In contrast, higher doses of L-AmB (up to 30<!--> <!-->mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by <em>Leishmania infantum</em> acquired in the Americas and Europe the usual dose of L-AmB is 20-21<!--> <!-->mg/kg. In HIV co-infected patients the required doses are usually higher, up to 60<!--> <!-->mg/kg, and if it is administered in a prophylactic schedule after the treatment of VL relapses are reduced. L-AmB has shown synergism with other antiparasitic drugs, especially with paromomycin in the Indian subcontinent and with miltefosin in patients coinfected with HIV in East Africa. Due to its efficacy and safety profile, L-AmB is the first therapeutic option for VL.</p></div>","PeriodicalId":21291,"journal":{"name":"Revista Iberoamericana De Micologia","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.riam.2021.04.002","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Iberoamericana De Micologia","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130140621000267","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
A review on the current evidence of the efficacy and security of liposomal amphotericin B (L-AmB) for the treatment of visceral leishmaniasis (VL) has been performed. In the Indian subcontinent, a single dose of 10 mg/kg has shown effectiveness in the treatment of VL due to Leishmania donovani. In contrast, higher doses of L-AmB (up to 30 mg/kg) are required in Africa to treat a VL of the same etiology. When treating VL by Leishmania infantum acquired in the Americas and Europe the usual dose of L-AmB is 20-21 mg/kg. In HIV co-infected patients the required doses are usually higher, up to 60 mg/kg, and if it is administered in a prophylactic schedule after the treatment of VL relapses are reduced. L-AmB has shown synergism with other antiparasitic drugs, especially with paromomycin in the Indian subcontinent and with miltefosin in patients coinfected with HIV in East Africa. Due to its efficacy and safety profile, L-AmB is the first therapeutic option for VL.
期刊介绍:
Revista Iberoamericana de Micología (Ibero-American Journal of Mycology) is the official journal of the Asociación Española de Micología, Asociación Venezolana de Micología and Asociación Argentina de Micología (The Spanish, Venezuelan, and Argentinian Mycology Associations). The Journal gives priority to publishing articles on studies associated with fungi and their pathogenic action on humans and animals, as well as any scientific studies on any aspect of mycology. The Journal also publishes, in Spanish and in English, original articles, reviews, mycology forums, editorials, special articles, notes, and letters to the editor, that have previously gone through a scientific peer review process.